Alethia Young

Phil Nadeau

Graig Suvannavejh

Mani Foroohar

Tyler Van Buren

Luca Issi

Patrick Dolezal

Dane Leone

Joon Lee

Tara Bancroft

- Adverum Biotechnologies, Inc. has **completed screening** for its pivotal Phase 3 ARTEMIS trial, which evaluates **Ixo-vec for wet age-related macular degeneration (wet AMD)**.  **[1501756_0001193125-25-210068_d937976dex991.htm:1]** 
- The completion of screening occurred **ahead of expectations**.  **[1501756_0001193125-25-210068_d937976dex991.htm:1]** 
- **Full enrollment** for the ARTEMIS trial is now anticipated in **Q4 2025**, an acceleration from the previous expectation of Q1 2026.  **[1501756_0001193125-25-210068_d937976dex991.htm:1]** 
- The **topline data readout** for the ARTEMIS trial has been **accelerated to Q1 2027**.  **[1501756_0001193125-25-210068_d937976dex991.htm:1]**

Adverum Biotechnologies Completes Screening for Pivotal Phase 3 ARTEMIS Trial, Accelerates Timelines

Adverum Biotechnologies (ADVM)